LEXX

0.698

0.41% -0.0029

Handel nachbörslich: .68 -0.018 -2.58%

Lexaria Bioscience Corp (LEXX)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$0.7009

Offen:

$0.7

24-Stunden-Volumen:

198.04K

Relative Volume:

0.32

Marktkapitalisierung:

$17.37M

Einnahmen:

$411.00K

Nettoeinkommen (Verlust:

$-4.85M

KGV:

-1.5864

EPS:

-0.44

Netto-Cashflow:

$-4.88M

1W Leistung:

+13.13%

1M Leistung:

-34.15%

6M Leistung:

-20.18%

1J Leistung:

-68.84%

1-Tages-Spanne:

$0.66

$0.70

1-Wochen-Bereich:

$0.555

$0.7197

52-Wochen-Spanne:

$0.46

$2.295

Lexaria Bioscience Corp Stock (LEXX) Company Profile

Firmenname

Lexaria Bioscience Corp

Sektor

Healthcare (1116)

Branche

Biotechnology (620)

Telefon

250-765-6424

Adresse

100 - 740 MCCURDY ROAD, KELOWNA

Mitarbeiter

Twitter

Nächster Verdiensttermin

2025-07-28

Neueste SEC-Einreichungen

LEXX's Discussions on Twitter

Vergleichen Sie LEXX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
LEXX Lexaria Bioscience Corp	0.698	17.44M	411.00K	-4.85M	-4.88M	-0.44
VRTX Vertex Pharmaceuticals Inc	484.15	118.84B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	812.27	81.61B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	422.50	53.69B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	822.94	49.49B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	176.00	37.34B	447.02M	-1.18B	-906.14M	-6.1812

Lexaria Bioscience Corp Aktie (LEXX) Neueste Nachrichten

Jan 02, 2026

Growth Value: Is Lexaria Bioscience Corp Equity Warrant stock dividend yield sustainable2025 Key Lessons & Technical Pattern Based Buy Signals - moha.gov.vn

Jan 02, 2026

Lexaria Bioscience (LEXX) Expected to Announce Earnings on Friday - Defense World

Jan 02, 2026

Jan 01, 2026

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 - New Castle News

Jan 01, 2026

Dec 31, 2025

Lexaria releases additional results from Phase 1b study GLP-1-H24-4 - Yahoo Finance

Dec 31, 2025

Dec 30, 2025

Lexaria’s Phase 1b GLP-1 Study Shows Comparable Metabolic Outcomes and Encouraging Blood Pressure Data for DehydraTECH Platform - TipRanks

Dec 30, 2025

Lexaria Bioscience (LEXX) Reports Promising Results from Phase 1 - GuruFocus

Dec 30, 2025

Drug trial in overweight patients ties CBD formula to lower blood pressure - Stock Titan

Dec 30, 2025

Lexaria Bioscience (NASDAQ:LEXX) Shares Up 5.5% – Here’s What Happened - Defense World

Dec 30, 2025

Dec 28, 2025

Sentiment Review: Is Lexaria Bioscience Corp Equity Warrant stock dividend yield sustainableMarket Performance Report & Stepwise Trade Execution Plans - moha.gov.vn

Dec 28, 2025

Dec 27, 2025

How geopolitical tensions affect Lexaria Bioscience Corp stock2025 Market Sentiment & Verified Entry Point Signals - moha.gov.vn

Dec 27, 2025

Lexaria Bioscience secures $3.5 million in direct offering to boost R&D - MSN

Dec 27, 2025

Dec 26, 2025

Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday - Benzinga

Dec 26, 2025

Lexaria Bioscience stock soars after ending $5M stock sale agreement with JonesTrading - MSN

Dec 26, 2025

Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright By Investing.com - Investing.com South Africa

Dec 26, 2025

Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright - Investing.com

Dec 26, 2025

LEXX: HC Wainwright & Co. Lowers Price Target to $1.50, Maintains Buy Rating | LEXX Stock News - GuruFocus

Dec 26, 2025

Dec 24, 2025

LEXX: DehydraTECH Formulation Reduces GLP-1 Agonist Side Effects - Research Tree

Dec 24, 2025

Primary Endpoint Successfully Achieved in Lexaria’s Phase 1b Study GLP-1-H24-4 - York Dispatch

Dec 24, 2025

Dec 23, 2025

Lexaria’s DehydraTECH-semaglutide cuts GLP-1 side effects in phase 1b trial and extends cash runway into 2026 - MSN

Dec 23, 2025

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus - Benzinga

Dec 23, 2025

Lexaria’s DehydraTECH-Semaglutide Cuts GLP-1 Side Effects in Phase 1b Trial and Extends Cash Runway Into 2026 - TipRanks

Dec 23, 2025

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 - Investing News Network

Dec 23, 2025

Experimental oral GLP-1 pill cuts side effects by nearly half in trial - Stock Titan

Dec 23, 2025

Dec 21, 2025

Is Lexaria Bioscience Corp. stock resilient to inflationJuly 2025 Market Mood & Weekly Consistent Profit Watchlists - Улправда

Dec 21, 2025

Dec 20, 2025

What momentum indicators show for Lexaria Bioscience Corp. stockPortfolio Growth Summary & AI Powered Market Trend Analysis - Улправда

Dec 20, 2025

Will Lexaria Bioscience Corp. stock deliver better than expected guidanceQuarterly Profit Review & Safe Capital Investment Plans - Улправда

Dec 20, 2025

Is Lexaria Bioscience Corp. stock a buy on dipsJuly 2025 Technicals & AI Optimized Trading Strategy Guides - Улправда

Dec 20, 2025

Portfolio Recap: What valuation multiples suggest for Lexaria Bioscience Corp. Equity Warrant stockBreakout Watch & Fast Entry and Exit Trade Plans - Улправда

Dec 20, 2025

Dec 19, 2025

Setup Watch: Is Lexaria Bioscience Corp. stock resilient to inflationSell Signal & Consistent Profit Trade Alerts - Улправда

Dec 19, 2025

How geopolitical tensions affect Lexaria Bioscience Corp. stockJuly 2025 Short Interest & Free Expert Verified Stock Movement Alerts - DonanımHaber

Dec 19, 2025

Will Lexaria Bioscience Corp. Equity Warrant stock benefit from AI adoptionWeekly Profit Summary & Risk Managed Trade Strategies - DonanımHaber

Dec 19, 2025

Published on: 2025-12-19 15:15:39 - DonanımHaber

Dec 19, 2025

Published on: 2025-12-19 14:32:21 - DonanımHaber

Dec 19, 2025

Is Lexaria Bioscience Corp. Equity Warrant stock trading at a premium valuationWeekly Earnings Recap & Weekly Top Stock Performers List - Улправда

Dec 19, 2025

Dec 18, 2025

Momentum Shift: Is Lexaria Bioscience Corp. Equity Warrant stock trading at a premium valuationJuly 2025 Breakouts & Daily Risk Controlled Trade Plans - Улправда

Dec 18, 2025